Subscribe to RSS
DOI: 10.1055/s-2001-17388
Idiopathic Interstitial Pneumonias: The Role of Environmental Triggers
Publication History
Publication Date:
26 September 2001 (online)
![](https://www.thieme-connect.de/media/srccm/200104/lookinside/thumbnails/10.1055-s-2001-17388-1.jpg)
ABSTRACT
or cryptogenic-fibrosing alveolitis is defined by a cluster of clinical, radiological, functional, and pathological features as well as by the exclusion of a recognized ``cause.'' The processes by which clinicians assign causes to nonspecific diseases are complex and often subjective. Furthermore, the disease is comparatively rare and is generally diagnosed only after the use of specialized techniques. As a result, the study of its etiological factors is difficult and has been largely unrewarding.
The distribution of the disease, so far as it is understood, favors the elderly and, to a lesser extent, males. In some countries mortality has been rising, although it is not clear whether this can be attributed to a diagnostic shift. Studies of occupational classifications among patients dying with the disease offer no striking etiological leads.
Four potential etiologies have been formally studied: occupational dust exposures, cigarette smoking, prescription drug use, and viral infections. Three studies have indicated a role for wood and metal dust exposures; methodological issues, however, leave room for remaining doubt and these studies require verification in other populations. There is little epidemiological evidence that cigarette smoking contributes to the disease, or that therapeutic drug use plays an important part. The role of viral infections, particularly those related to Epstein-Barr virus (EBV), is intriguing but remains largely unsubstantiated.
KEYWORD
Idiopathic pulmonary fibrosis - epidemiology - mortality - occupation - smoking
REFERENCES
- 1 Turner-Warwick M. In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many?. Thorax . 1998; 53 53-59
- 2 Sharma O P, Chan K. Idiopathic interstitial pneumonitis/ fibrosis: a historical note. Current Opinion in Pulmonary Medicine . 1999; 5 275-277
- 3 Hubbard R, Johnston I, Coultas D B, Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax . 1996; 51 711-716
- 4 Wells A U, Cullinan P, Hansell D M. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respri Crit Care Med . 1994; 149 1583-1590
- 5 Johnston I, Britton J, Kinnear W, Logan R. Rising mortality from cryptogenic fibrosing alveolitis. Br Med J . 1990; 301 1017-1021
- 6 Coultas D B, Hughes M P. Accuracy of mortality data for interstitial lung diseases in New Mexico, USA. Thorax . 1996; 51 717-720
- 7 Harris J M, Cullinan P, McDonald J C. Occupational distribution and geographical clustering of deaths certified to cryptogenic fibrosis alveolitis in England and Wales. Chest . 2001; 119(2) 428-433
- 8 Iwai K, Mori T, Yamada N. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med . 1994; 150 670-675
- 9 De Vuyst P, Domortier P, Rickaert F. Occupational lung fibrosis in an aluminium polisher. Eur J Respir Dis . 1986; 68 131-140
- 10 Bartter T, Irwin R S, Abraham J L. Zirconium compound-induced pulmonary fibrosis. Arch Intern Med . 1991; 151 1197-201
- 11 Townshend R H. Acute cadmium pneumonitis: a 17-year follow-up. Br J Indust Med . 1982; 39 411-412
- 12 Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis?. <~>A case-control study of environmental exposure to dust. Br Med J . 1990; 301 1015-1017
- 13 Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet . 1996; 347 284-289
- 14 Hubbard R, Cooper M, Antoniak M. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet . 2000; 355 466-467
- 15 De Cremoux R, Bernaudin J-F, Laurent P, Brochard P, Bignon J. Interactions between cigarette smoking and the natural history of idiopathic pulmonary fibrosis. Chest . 1990; 98(1) 71-76
- 16 Baumgartner K B, Samet J M, Stidley C A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med . 1997; 155 242-248
- 17 Zitnik R J, Matthay R A. Drug-induced lung disease. In: Schwarz MI, King TE, eds. Interstital Lung Disease Hamilton, ON, Canada: BC Decker 1998: 423-449
- 18 Blum R, Carter S, Agre K. A clinical review of bleomycin: a new antineoplastic agent. Cancer . 1973; 31 903-913
- 19 Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med . 1998; 157 743-747
- 20 Hubbard R, Venn A, Britton J. Exposure to antidepressants and the risk of cryptogenic fibrosing alveolitis: a case-control study. Eur Respir J . 2000; 16 409-413
- 21 Egan J J, Woodcock A A, Stewart J P. Viruses and idiopathic pulmonary fibrosis. Eur Respir J . 1997; 10 1433-1437
- 22 Vergnon J M, Vincent M, De The G. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association. Lancet . 1984; ii 768-770
- 23 Egan J J, Stewart J P, Hasleton P S. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax . 1995; 50 1234-1239
- 24 Egan J J, Stewart J P, Hasleton P S. EBV PRC (Raji I) in idiopathic pulmonary fibrosis and sarcoidosis. Am J Respir Crit Care Med . 1997; 155 A315
- 25 Wangoo A, Nicholson A G, Diss T C. Cryptogenic pulmonary fibrosis does not appear associated with Epstein-Barr virus infection. Thorax . 1996; 51(Suppl 3) A11
- 26 Kuwano K, Nomoto R, Hagimoto N. Detection of adenovirus EIA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J . 1997; 10 1445-1449
- 27 Ueda T, Ohta K, Suzuki N. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis . 1992; 146 266-268
- 28 Meliconi R, Andreone P, Fasano L. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax . 1996; 51 315-317
- 29 Prieto J, Sangro B, Beloqui O. Ribavarin in desquamative interstitial pneumonia. Chest . 1988; 93 446-447
- 30 Agusti C, Xaubet A, Ballester E. Aerolised ribavarin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study. Thorax . 1993; 48 68-69